A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATE

A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATE

Abstract In this phase II, single arm trial (ACTRN12617000720314), we investigate if alternating osimertinib and gefitinib would delay the development of resistance to osimertinib in advanced, non-small cell lung cancer (NSCLC) with the epidermal growth factor receptor (EGFR) T790M mutation (n = 47)...

Full description

Bibliographic Details
Main Authors: Lavinia Tan, Chris Brown, Antony Mersiades, Chee Khoon Lee, Thomas John, Steven Kao, Genni Newnham, Kenneth O’Byrne, Sagun Parakh, Victoria Bray, Kevin Jasas, Sonia Yip, Stephen Q. Wong, Sarah Ftouni, Jerick Guinto, Sushma Chandrashekar, Stephen Clarke, Nick Pavlakis, Martin R. Stockler, Sarah-Jane Dawson, Benjamin J. Solomon
Format: Article
Language:English
Published: Nature Portfolio 2024-02-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-024-46008-1

Internet

https://doi.org/10.1038/s41467-024-46008-1

Similar Items